期刊文献+

吉西他滨聚氰基丙烯酸正丁酯纳米粒的制备工艺 被引量:8

Preparation of gemcitabine polybutylcyanoacrylate nanoparticles
下载PDF
导出
摘要 目的优化吉西他滨聚氰基丙烯酸正丁酯(GCTB-PBCA-NP)纳米粒的制备工艺。方法以GCTB-PBCA-NP的粒径、包封率和载药量为指标,在单因素考察的基础上,通过正交设计优化处方和制备工艺。结果制备的GCTB-PBCA-NP平均粒径为(112±9)nm,包封率为(54.12±2.43)%,载药量为(11.08±0.89)%。结论制备的纳米给药系统为拓展吉西他滨的临床给药新剂型提供了参考。 Objective To optimize the preparation process of gemcitabine polybutylcyanoacrylate nanoparticles (GCTB- PBCA-NP). Methods According to the particle size, the entrapment efficiency and the loading quantity of GCTB-PBCA-NP, single factor analysis was carried out to optimize the component composition and preparation process based on an orthogonal design. Results The mean particle size of the NP was (112±9) nm with an entrapment efficiency of (54.12±2.43)% and drug loading of (11.08±0.89)%. Conclusion An optimized nanoparticular drug delivery system is obtained by emulsion polymerization.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2007年第11期1653-1656,共4页 Journal of Southern Medical University
基金 广东省科技计划项目(2005B30101008)~~
关键词 吉西他滨 聚氰基丙烯酸正丁酯 纳米粒 乳化聚合法 正交设计 gemcitabine polybutylcyanoacrylate nanoparticles emulsion polymerization orthogonal design
  • 相关文献

参考文献6

二级参考文献44

  • 1张志荣,廖工铁.聚氰基丙烯酸酯毫微球的研究进展[J].中国药学杂志,1994,29(6):323-326. 被引量:13
  • 2张志荣,廖工铁.聚氰基丙烯酸正丁酯毫微球中米托蒽醌的含量测定[J].中国药学杂志,1994,29(7):422-424. 被引量:8
  • 3隋因,刘宝庆,夏东亚.冷冻干燥法制备阿糖胞苷冻干脂质体粉针研究[J].中国医院药学杂志,1995,15(11):487-490. 被引量:17
  • 4[1]Kerr JZ, Berg SL, Dauser R, et al. Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates[J]. Cancer Chemother Pharmacol, 2001, 47(5): 411-414.
  • 5[2]Kiani A, Kohne CH, Franz T, et al. Pharmacokinetics of gemcitabine in a patient with end-stage renal disease:ef fective clearance of its main metabolite by standard hemodialysis treatment[J]. Cancer Chemother Pharmacol, 2003, 51(3): 266-270.
  • 6[3]Pestieau SR, Stuart OA, Chang D, et al. Pharmacokinetics of intraperitoneal gemcitabine in rat model [J]. Tumori, 1998,84(6):706-711.
  • 7[4]Freeman KB, Anliker S, Hamilton M, et al. Validated as says for the determination of gemcitabine in human plas ma and urine using high-performance liquid chromatog raphy with ultraviolet detection[J]. Journal of Chromatog raphy B, 1995, 665(1):171-181.
  • 8[5]Perez-Manga G, Lluch A, Alba E, et al. Gemcitabine in ombination with doxorubicin in advanced breast cancer: final results of a phase Ⅱ pharmacokinetic trial[J]. J Clin Oncol, 2000,18(13):2545-2552.
  • 9[6]Grunewald R, Abbruzzese JL, Tarassoff P, et al. Satura tion of 2', 2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase Ⅰ trial of gemcitabine[J]. Cancer Chemother Pharmacol, 1991,27 (4):258-2562.
  • 10[7]Esumi Y, Mitsugi K, Seki H, et al. Placental transfer, lacteal transfer and plasma protein binding of gemcitabine [J].Xenobiotica, 1994, 24(10):957-964.

共引文献18

同被引文献127

引证文献8

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部